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We previously showed that expression of the anti-HIV innate proteins human beta-defensin 2 (hBD2)
and hBD3 in adult oral epithelial cells reduces HIV transepithelial transmission by inactivation of virus.
However, fetal/infant oral epithelia lack beta-defensin expression, leading to transmission of HIV. The
mechanisms of hBD2- and hBD3-mediated HIV inactivation in adult oral epithelial cells are poorly
understood. Here we found that heparan sulfate proteoglycans (HSPGs) on the apical surfaces of epi-
thelial cells facilitate simultaneous binding of hBDs and HIV gp120 to the cell surface. HSPG-facilitated
binding of hBDs and HIV gp120 to the cell surface did not affect viral attachment. HBD2 or -3 coin-
ternalized with virions in endosomes, formed oligomers, and reduced infectivity of HIV. The anti-HIV
effect of combining hBD2 and hBD3 was substantially higher than that of the individual peptides. These
ﬁndings advance our understanding of the mechanisms of anti-HIV resistance in adult oral epithelium.
& 2015 Elsevier Inc. All rights reserved.Introduction
The mucosal epithelia of the oropharyngeal, gastrointestinal
and anogenital tracts play a critical role in initial HIV transmission;
however, viral transmigration via epithelium varies considerably
at different epithelial sites. For example, oral transmission of
HIV through adult oropharyngeal mucosal epithelium is rare: the
infection rate per oral sexual exposure is estimated to be 0.00–
0.04% (Page-Shafer et al., 2006; Tudor-Williams and Lyall, 1999;
UNAIDS, 2011). In contrast, mother-to-child transmission (MTCT)
of HIV through fetal/neonatal oral and gastrointestinal epithelia is
much more common. Without intervention, the rate of MTCT can
reach 30–45% (Boyle et al., 2013; Lehman and Farquhar, 2007;
UNAIDS, 2013; Wood et al., 2013). Likewise, HIV transmission is
about 10 times more frequent through cervicovaginal epithelium
than through adult oral epithelium (Anderson et al., 2010; Bag-
galey et al., 2010, 2013; Campo et al., 2006; Pope and Haase, 2003;
Rothenberg et al., 1998; Scully and Porter, 2000; Younai, 2001),Department of Medicine, San
364.
v).and HIV transmission through anal sex is estimated to be 18 times
higher than the risk through vaginal sex (Baggaley et al., 2010,
2013; Boily et al., 2009a, 2009b). Although the variability of HIV
transmission through different mucosal epithelial sites is well
documented, very little is known about the role of epithelial-
speciﬁc biological factors, including that of innate immune pro-
teins, in the modulation of transepithelial transmission of virus.
Mucosal epithelia express multiple epithelial-speciﬁc anti-HIV
innate immune proteins, including human beta-defensins 2
(hBD2), hBD3, and secretory leukocyte protease inhibitor (SLPI),
which may reduce viral mucosal transmission (Borrow et al., 2010;
Jana et al., 2005; Ma et al., 2004; McNeely et al., 1997; Sun et al.,
2005; Wahl et al., 1997; Wang et al., 2003, 2004; Weinberg et al.,
2006, 2011). However, expression of anti-viral innate proteins may
vary in mucosal epithelia at different geographic sites and could
depend on age. For example, adult oral mucosa constitutively
expresses high levels of hBD2, hBD3, and SLPI, but expression of
these innate proteins in fetal and infant oral epithelium is very low
(Dale et al., 2001; Dunsche et al., 2002; Jana et al., 2005; Mout-
sopoulos et al., 2007; Quinones-Mateu et al., 2003; Sun et al.,
2005; Tugizov et al., 2011). Expression of hBD2, hBD3, and SLPI in
the genital mucosa is not stable and depends on the menstrual
cycle; i.e., hBD3 and SLPI are expressed during the secretory phase,
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2003; Moriyama et al., 1999). Expression of hBD2, hBD3 and SLPI
in established polarized cervical epithelial cells in vitro is barely
detectable (Tugizov et al., 2011). There are higher levels of innate
protein expression in saliva than in rectal ﬂuid, as shown by
comparative proteomic analysis (Romas et al., 2014).
Defensins are small, 3- to 5-kDa cysteine-rich cationic innate
proteins with a broad spectrum of antimicrobial and antiviral
properties (Dhople et al., 2006; Schroder and Harder, 1999). The
anti-HIV functions of hBD2 and hBD3 have been investigated in
both X4- and R5-tropic viruses (Sun et al., 2005; Wang et al., 2003,
2004; Weinberg et al., 2006). These defensins bind to the HIV
envelope and inactivate both X4- and R5-tropic viruses (Quinones-
Mateu et al., 2003; Sun et al., 2005; Wang et al., 2003, 2004;
Weinberg et al., 2006). hBD2 and hBD3 downregulate C-X-C che-
mokine receptor type 4 and inhibit entry of X4-tropic HIV-1
(Quinones-Mateu et al., 2003). hBD2 and hBD3 also inhibit HIV
replication at an early stage by reducing reverse transcription
activity of the virus (Sun et al., 2005).
Although the anti-HIV activity of hBD2 and hBD3 has been
investigated in HIV-susceptible CD4þ T lymphocytes and periph-
eral blood mononuclear cells (PBMC), the molecular mechanisms
of antiviral functions of defensins in mucosal epithelial cells, the
ﬁrst target for viral transmission, have been poorly investigated.
HIV mucosal transmission is initiated by transcytosis of virions
through epithelial cells or by paracellular passage of virus between
cells if tight junctions are disrupted (Mesquita et al., 2009; Tugizov
et al., 2012). HIV transepithelial transcytosis has been shown by
using polarized epithelial cells of oral, intestinal, vaginal, and
endometrial origin with intact tight junctions (Bobardt et al., 2007;
Bomsel, 1997; Gupta et al., 2013; Kinlock et al., 2014; Kohli et al.,
2014; Meng et al., 2002; Saidi et al., 2007; Tugizov et al., 2011).
HIV transcytosis through fetal and infant oral mucosal epithe-
lium (Tugizov et al., 2011, 2012) may play a critical role in mother
to child transmission (MTCT), which is an important pathway for
the spread of HIV (UNAIDS, 2013). MTCT of HIV via oral mucosal
epithelia may originate from amniotic ﬂuid in utero (Jaspan et al.,
2004; Maiques et al., 2003; Mundy et al., 1987), from amniotic and
cervicovaginal ﬂuids at birth, and from breast milk postnatally
(Nussenblatt et al., 2005; Semba, 2000; Semba and Neville, 1999;
Willumsen et al., 2000).
HIV transmitted through adult oral epithelial cells is rendered
noninfectious, whereas virions that pass through fetal oral epi-
thelial cells remain highly infectious (Tugizov et al., 2011, 2012).
Inactivation of HIV by adult oral epithelial cells is mediated by
high-level expression of hBD2 and hBD3, and their lack of
expression in fetal and infant oral epithelium leads to the passage
of infectious virions. The mechanisms of hBD-associated protec-
tion of HIV transmission through adult oral epithelium are poorly
understood. We hypothesized that since heparan sulfate pro-
teoglycans (HSPGs) bind to HIV gp120 and hBD3 (Bobardt et al.,
2003, 2004b, 2007; Hazrati et al., 2006), this interaction may play
a role in enhancing innate anti-viral functions of hBDs in oral
mucosal epithelium. HSPGs are membrane glycoproteins com-
posed of a core protein and one or more heparan sulfate glyco-
saminoglycan chains—linear polysaccharides composed of alter-
nating N-acetylated or N-sulfated glucosamine units and uronic
acids (Sarrazin et al., 2011). Here we investigated the possible
interactions of HSPGs with hBDs and HIV in oral epithelium and
their role in hBD2- and hBD3-mediated inactivation of HIV in oral
epithelial cells. We used polarized infant tonsil epithelial cells as a
model system for HSPG-hBD-HIV interactions since these cells
may serve as a better model system for MTCT of HIV. Herein, we
report that HSPGs on the apical surfaces of tonsil epithelial cells
facilitate simultaneous binding of hBDs and HIV to the cell surface.
Subsequent cointernalization of hBDs with HIV into vesicularcompartments of oral epithelial cells leads to a reduction in
infectious activity of intracellular virus.Results
Expression of hBD2 and hBD3 in polarized adult and infant tonsil
epithelial cells
We previously showed that the high-level expression of hBD2
and hBD3 in adult oral mucosal epithelium is in contrast to the low
level or lack of expression of these proteins in the infant oral
epithelium (Tugizov et al., 2011). Here we established polarized
epithelial cells from primary tonsil keratinocytes of 3 independent
adult and 3 independent infant donors. Cells were grown in
Transwell ﬁlter inserts for 10–14 days. All cells expressed tight
junction protein zonula occludens (ZO-1) in a ring shape (Fig. 1A),
and transepithelial resistance was 600–700Ω/cm2, indicating
development of epithelial polarity. Immunostaining of adult AT#1
and infant IT#1 polarized epithelial cells for hBD2 and hBD3
showed strong expression of both proteins in the adult tonsil
epithelial cells (Fig. 1B). About 95% of the adult cells were strongly
positive for both hBD2 and hBD3. In contrast, hBD2 and hBD3
expression in infant tonsil epithelial cells was greatly reduced
(Fig. 1B). These ﬁndings were corroborated by two other tonsil
keratinocyte cultures that were isolated from independent donors
of adult and infant origin (data not shown). Furthermore, Western
blot analysis conﬁrmed the immunostaining data showing that
hBD2 and hBD3 were detected in all 3 adult epithelial cell lines
(Fig. 1C). In contrast, a Western blot of infant tonsil cultures iso-
lated from 3 independent donors showed only a trace amount of
hBD2 (Fig. 1B). hBD3 was not detected in these infant cells.
HSPGs facilitate hBD2 and hBD3 binding to the apical surfaces
of polarized oral epithelial cells
We have shown that adult oral epithelial cells express and
secrete hBD2 and hBD3 and inactivate transcytosed HIV (Tugizov
et al., 2011). However, it was not clear whether HIV is inactivated
upon binding of the virus to the cell surface by secreted hBDs, or
during viral transcytosis in the vesicular/endosomal compart-
ments, or both. To determine if hBDs inactivate HIV before trans-
cytosis upon virion attachment to the cell surface, we ﬁrst exam-
ined hBD binding to the apical cell surface. Hazrati showed that
hBD3 binds to HSPG, but the study was done using a cell-free
system (Hazrati et al., 2006). Here, we examined hBD2 and hBD3
binding to HSPG in polarized infant epithelial cells. A domain-
speciﬁc assay of HSPG in polarized adult and infant epithelial cells
showed that HSPG was expressed in both apical and basolateral
membranes of polarized cells of adult and infant origins (Fig. 2A).
Heparinase treatment of infant oral epithelial cells removed the
majority of HSPGs; i.e., approximately 70% of cells stained nega-
tively after heparinase treatment (Fig. 2B).
To determine the binding of hBD2 and hBD3 to apical HSPG, the
apical membrane of polarized infant epithelial cells was treated or
not treated with heparinase, and recombinant hBD2 and hBD3
binding to HSPG was examined by surface biotinylation assay. The
data showed that both hBDs bound to the cell surface. Quantitative
analysis of protein bands that bound to the cell surface showed
that treatment with heparinase substantially (i.e., E80–90%)
reduced hBD binding (Fig. 2C). To conﬁrm equal protein loading in
heparinase-treated and -untreated samples, we examined apically
expressed T-cell immunoglobulin and mucin domain 1 (TIM-1)
protein (Kondratowicz et al., 2011) in the surface biotinylated
samples. Similar levels of TIM-1 detection indicated that protein
loading was equal in heparinase-treated and -untreated samples.
Fig. 1. Expression of anti-HIV innate proteins hBD2 and hBD3 in adult but not infant oral epithelial cells. (A) Adult AT#1 and infant IT#1 epithelial cells were grown under
polarized conditions and immunostained for ZO-1 (green). Cells were analyzed by confocal microscopy, and representative XY images in single plane are shown. Cell nuclei
are counterstained in blue. (B) Polarized AT#1 and IT#1 cells were immunostained for hBD2 and hBD3 (both in green). (C) Polarized adult and infant epithelial cells isolated
from independent donors were lysed, and hBD2 and hBD3 were detected by Western blot assay. Beta-actin was used as a loading control.
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HSPG facilitate the binding of both hBD2 and hBD3 to the apical
surface of polarized oral epithelial cells.Previously, we showed that polarized adult and fetal oral epi-
thelial cells express HIV coreceptors CXCR4, CCR5 and galacto-
sylceramide (GalCer) on the apical surfaces of epithelial cells
Fig. 2. HSPGs facilitate hBD2 and hBD3 binding to the apical surfaces of infant oral epithelial cells. (A) HSPGs were detected in apical (AP) and basolateral (BL) membranes of
polarized adult AT#1 and infant IT#1 tonsil epithelial cells by domain-speciﬁc biotinylation. (B) The apical and basolateral surfaces of infant IT#1 polarized epithelial cells
were treated with heparinase, and untreated cells served as a control. Cells were ﬁxed and immunostained with mouse monoclonal antibodies (10E4) against HSPG (green).
(C) The apical surfaces of infant IT#1 polarized epithelial cells were treated with heparinase or untreated. Recombinant hBD2 and hBD3 (100 mg/ml each) were added to
apical membranes, and cells were incubated for 30 min at 4 °C. Cells were washed, cell surfaces were biotinylated, and biotinylated proteins were precipitated with
streptavidin–agarose beads. hBD2 and hBD3 were detected in the streptavidin precipitates by Western blot assay (upper panels). To verify equal protein loading in the
heparinase-treated and untreated samples, these samples were examined for TIM-1 protein (lower panels). The mean densities of pixels in the hBD2 and hBD3 bands were
measured by ImageJ software; the results for each gel are shown as a bar graph under each blot. (D) Polarized infant oral epithelial cells (IT#1) were immunostained for
CCR5, CXCR4 and GalCer (all green). (E) Polarized IT#1 cells were preincubated with antibodies to CCR5, CXCR4 and GalCer at 4 °C for 1 h and after washing were incubated
with hBD2 or hBD3 (100 mg/ml of each) for 30 min at 4 °C. Cells were washed and hBDs were detected by domain-speciﬁc labeling assay. All experiments presented in panels
A, B and C were performed 3 times using IT#1, IT#2 and IT#3 cells, and representative data from IT#1 are presented. Experiments in panels D and E were repeated twice by
using IT#1 and IT#3, and representative IT#1 data are presented.
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CXCR4, CCR5 and GalCer showed that infant oral epithelial cells
were also positive for these proteins (Fig. 2D). Approximately 30%
of cells were positive for CXCR4 and CCR5, and 50% were positivefor GalCer. To determine if these HIV coreceptors play a role in hBD
binding to the apical cell surface, we preincubated polarized tonsil
epithelial cells with antibodies against CXCR4, CCR5 and GalCer.
HBD2 and hBD3 binding was then examined in a domain-speciﬁc
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bodies inhibit or reduce hBD binding to infant tonsil epithelial
cells (Fig. 2E), indicating that these coreceptors do not play a role
in hBD interaction with tonsil epithelial cells.
HSPGs facilitate simultaneous binding of hBD2 and hBD3, and HIV
gp120 to the apical surfaces of polarized oral epithelial cells
Above, we showed that HSPGs facilitate hBD2 and hBD3
binding to the apical surfaces of infant oral epithelial cells. It has
been shown that HSPG also bind to HIV gp120 (Bobardt et al.,
2003, 2004b, 2007), suggesting that HSPG may simultaneously
interact with hBDs and HIV gp120 on the apical surface of polar-
ized oral epithelial cells. To study this possibility, polarized infant
cells were treated or not treated with heparinase and incubated
with hBD2 and hBD3 for 30 min at 4 °C. One set of cells was not
incubated with hBDs. After extensive washing, cells were incu-
bated with HIV-1SF33 for 1 h at 4 °C, and gp120 was immunopre-
cipitated. Western blot analysis of hBD2 and hBD3 in the gp120
precipitates showed that gp120 coprecipitated with both hBD2
and hBD3 (Fig. 3A, left upper panels). In cells without hBD treat-
ment, coprecipitation of gp120 with hBD2 and hBD3 was not
detected (Fig. 3A, right panel). Heparinase treatment substantially
reduced gp120 coprecipitation with hBD2 and hBD3. To determine
if heparinase treatment affects HIV binding to the cell surface, we
examined the presence of gp120 in the immunoprecipitated
samples of the hBD2- or hBD3- treated cells (Fig. 3A, left middle
panels). Quantitative analysis of the Western blot data showedFig. 3. HSPGs facilitate hBD2 and hBD3 binding to HIV gp120. (A) The apical membranes
each) were added to the apical surfaces, incubated at 4 °C for 30 min, and, after extensive
washed, and gp120 was immunoprecipitated. (Left upper panels) hBD2 and hBD3 w
Immunoprecipitated samples were blotted with anti-gp120 antibodies. (Left lower panels
software and shown as a bar graph under each blot. IgG LC, immunoglobulin light ch
heparinase or untreated and gp120 was precipitated in absence of hBD2 and hBD3. (B) H
the presence or absence of puriﬁed HSPGs (100 mg/ml) in cell culture media for 1 h at 37
Western blot under reducing conditions. (Left, middle panels) Immunoprecipitated samp
bands were quantiﬁed by ImageJ and mean densities of pixels are shown as a bar grap
treated and HIV bound cells were blotted with normal mouse IgG. (C) hBD2 or hBD3 w
remove unbound hBDs, cells were washed and HIV-1SF33 (200 ng/ml) was added for 1 h a
separated under nonreducing conditions in 16% Tris-glycine gel. hBD2 and hBD3 were
pendent experiments using infant IT#1 and IT#3 tonsil epithelial cells.that heparinase treatment reduced the amount of gp120 in the
immunoprecipitated samples by approximately 30% and 60% in
hBD2 and hBD3-treated cells, respectively, compared to untreated
cells (Fig. 3A, left lower panels). The reduction of gp120, i.e., HIV
binding to the cell surface, correlated with the reduction of gp120
coprecipitation with hBD2 and hBD3. Thus, the data in Figs. 2C and
3A show that HSPGs bind simultaneously to hBD2 and hBD3 and
to HIV gp120 on the apical cell surfaces of oral epithelial cells.
To conﬁrm this ﬁnding, we examined hBD2 and hBD3 binding
to HIV gp120 in the presence or absence of HSPGs using puriﬁed
heparan sulfate proteoglycan. Incubation of HIV-1SF33 with hBD2
or hBD3 in the presence of puriﬁed HSPGs in cell culture media for
1 h at 37 °C led to binding of both hBDs to gp120 (Fig. 3B, left
upper panels). In contrast, in the absence of HSPGs, hBD2 and
hBD3 binding to HIV gp120 was not detected, thus showing that
the simultaneous binding of HSPGs to hBD2 and hBD3 and to HIV
gp120 is critical for gp120 coprecipitation with hBDs. Presence of
gp120 in these samples was approximately similar (Fig. 3B, left
middle and lower panels). Chondroitin sulfate did not facilitate
hBD binding to HIV gp120 (data not shown), indicating the speciﬁc
role of HSPGs in binding of hBD2 and hBD3 to HIV gp120.
To verify the antibody speciﬁcity in the immunoprecipitation
experiments, gp120-immunoprecipitated samples of hBD2-
(Fig. 3B, right panel) and hBD3 (data not shown)-treated and HIV
bound cells were blotted with normal mouse IgG. Lack of higher
bands similar with gp120 and lower bands similar with hBD2 and
hBD3 indicate that the anti-gp120, and hBD2 and hBD3 antibodies
speciﬁcally recognized these proteins.of IT#1 cells were treated with heparinase or untreated. hBD2 and hBD3 (100 mg/ml
washing, HIV-1SF33 (200 ng/ml) was added. Cells were incubated for 1 h at 4 °C and
ere detected in the gp120 precipitates by Western blotting. (Left middle panels)
) The mean densities of pixels in the gp120 protein bands were measured by ImageJ
ain; IgG HC, immunoglobulin heavy chain. (Right panel) Cells were treated with
IV-1SF33 at 100 ng p24/ml was incubated with hBD2 or hBD3 (100 mg/ml of each) in
°C. (Left upper panels) HIV-1SF33 gp120 was precipitated and hBDs were detected by
les were blotted with anti-gp120 antibodies. (Left lower panels) The gp120 protein
h under each blot. (Right panel) HIV gp120 immunoprecipitated samples of hBD2
as added to the apical surfaces of polarized infant IT#1 cells for 30 min at 4 °C. To
t 4 °C. Cells were washed, lysed, and gp120 was immunoprecipitated. Proteins were
detected by Western blotting. A, B and C. Similar results were obtained in 2 inde-
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coprecipitated hBD2 and hBD3 was examined by Western blot under
nonreducing conditions. The results show that hBD2 and hBD3 were
detected at 5 kDa (Fig. 3C), which was consistent with their
monomers, indicating that hBD binding to the cell surface and HIV
gp120 did not lead to their oligomer formations. These data indicate
that HIV gp120 binding to hBD2 and hBD3 is indirect and is facilitated
by HSPG, which binds to both HIV gp120 and hBDs.
HSPG-mediated hBD2 and hBD3 binding to the apical surfaces of
polarized cells did not affect HIV attachment and did not alter
infectivity of cell-bound virus
To study the role of hBD2 and hBD3 in HIV's binding to the
apical surface of polarized cells and the infectivity of cell-bound
virus, we performed an HIV binding and infectivity experiment in
the presence or absence of hBD2 and hBD3 in the infant cells. One
set of cells was preincubated with antibodies against HSPG, and
another set was pretreated with heparinase. HBD2 or hBD3 (1, 10,
or 100 mg/ml each) was added to the apical surfaces for 30 min at
4 °C. The highest concentrations of hBD2 and hBD3 in this study
were established on the basis of their higher level of local
expression in oral epithelium, which may reach 100 mg in 100-mm-
thick epithelial tissue (Shi et al., 1999). Relevant concentrations of
hBDs (from 0.8 mg/ml to 100 mg/ml) were used in other studies
(Quinones-Mateu et al., 2003; Sun et al., 2005; Wang et al., 2003,
2004; Weinberg et al., 2006). Cells without hBDs served as a
control. Analysis of the cytotoxicity assay and measurement of
transepithelial resistance of polarized cells treated with 100 mg/ml
hBD2 and/or hBD3 for 24 h showed that hBDs were not cytotoxic
to the cells (Fig. 4A upper panel) and did not reduce transepithelial
resistance (TER) of polarized cells (Fig. 4A lower panel).Fig. 4. hBD and HIV interaction does not affect virus attachment to the cell surface and
were incubated with hBD2, hBD3 and hBD2þhBD3 for 24 h and cell viability (upper p
pithelial resistance. (B) Polarized cells were preincubated with antibodies to HSPG or trea
and hBD3 in increasing concentrations for 1 h at 4 °C. Cells were washed, and HIV-1SF33, H
of polarized cells for 1 h at 4 °C. Cells were washed, and HIV binding was examined by p2
HIV exposed cells for attachment were washed, homogenized, and used to infect TZM
luciferase unit. These experiments were performed twice using IT#1 and twice in IT#3 c
IT#1 and TZM-bl cells were grown under polarized and nonpolarized conditions, respec
used as a loading control.Previously, we showed that hBD2 and hBD3 may play a role in
inactivation of dual-tropic, R5 and X4-tropic HIV-1, which were
transcytosed through polarized oral epithelial cells. Therefore, to
determine the role of hBDs in HIV attachment, we used dual-tropic
HIV-1SF33, R5-tropic HIV-1SF170 and X4-tropic HIV-192UG029 viruses.
After washing of cells from unbound virions, attachment of HIV-
1SF33, HIV-1SF170 and HIV-192UG029 viruses was examined by p24
ELISA assay. Antibodies against HSPG and heparinase treatment
reduced HIV attachment to the apical surface of polarized cells,
indicating a role for HSPG in viral binding. However, increasing
concentrations of hBD2 and hBD3 did not reduce HIV attachment
(Fig. 4B, upper panel) to the apical membranes, indicating that
HSPG-facilitated binding of hBDs to gp120 may not be critical for
viral attachment to the cell surface.
We next examined the infectivity of apically-bound HIV in the
presence or absence of hBD2 and hBD3 in concentrations similar
to those in the attachment assay. Infection of TZM-bl cells with
apically-bound HIV-1SF33, HIV-1SF170 and HIV-192UG029 virions
showed that hBD2 and hBD3 did not reduce the infectious activity
of HIV attached to the cell surface (Fig. 4B, lower panel), indicating
that hBDs do not play a role in viral inactivation before its inter-
nalization and transcytosis.
Comparative analysis of HSPG expression in TZM-bl and polarized
infant tonsil epithelial IT#1 cells by Western blot showed that TZM-
bl cells also express HSPGs; however, their expression is substantially
lower than that in tonsil cells (Fig. 4C). Expression of HSPG in TZM-bl
cells is involved in HIV binding (Bobardt et al., 2004a; Mondor et al.,
1998). TZM-bl cells also express the main viral receptor CD4 and
coreceptors CCR5 and CXCR4, which mediate viral attachment and
entry (Platt et al., 1998; Wei et al., 2002).does not inactivate cell-bound virus. (A) Polarized infant IT#1 tonsil epithelial cells
anel) and TER (lower panel) were examined. RLU, relative light units. TER, transe-
ted with heparinase. (Upper panel) Next, sets of cells were preincubated with hBD2
IV-1SF170, or HIV-192UG029 virions (40 ng/ml each) were added to the apical surfaces
4 ELISA. Bars indicate standard errors of the means (n¼3). (Lower panel). hBDs and
-bl cells. After 48 h HIV infection was evaluated by luciferase assay. RLU, relative
ells, and average data of four experiments was presented. (C) Infant tonsil epithelial
tively, and HSPGs were detected by Western blot assay. Detection of beta-actin was
Fig. 5. HSPG-mediated cointernalization of hBDs and HIV into polarized infant tonsil epithelial cells. (A) Recombinant hBD2 and hBD3 (100 mg/ml each) were added to the
apical surfaces of polarized infant IT#2 cells and incubated at 37 °C for 30 min. Untreated cells served as a control. Cells were ﬁxed, permeabilized and immunostained for
hBD2 and hBD3 (both in green) and analyzed by confocal microscopy. Cell nuclei are stained in red. Representative XY images in single plane are shown. (B) Cells were
treated with heparinase and dissociated with 0.25% trypsin to remove uninternalized hBDs from the cell surface, and intracellular hBD2 and hBD3 were detected by Western
blotting. The mean densities of pixels in the protein bands were measured by ImageJ software and the results for each gel are shown as a bar graph under each blot.
(C) Recombinant hBD2 or hBD3 was added to the apical surfaces of IT#2 polarized cells, which were incubated at 4 °C and 37 °C for 30 min. Then, uninternalized hBDs were
removed by heparinase and trypsin treatments, and internalized hBD2 and hBD3 were detected by Western blot assay. (D) IT#2 cells were treated with heparinase or not
treated, washed, and incubated with hBD2 and hBD3 for 30 min at 4 °C. Cells were washed and incubated with HIV-1SF33 for 1 h at 37 °C. Cells were dissociated with 0.25%
trypsin, and intracellular hBD2, hBD3 and HIV p24 were detected by Western blotting. B, C and D. The mean densities of pixels in the protein bands are shown as a bar graph
under each blot. (E) hBD2 and hBD3 were added to the apical surfaces of IT#2 polarized cells for 30 min at 4 °C. Then, cells were washed and incubated with HIV-1SF33 for
30 min at 37 °C. Cells were ﬁxed, immunostained for hBDs (red) and HIV (green), and examined by confocal microscopy. Yellow in merged panels (upper and middle raw)
indicates colocalization of HBDs with HIV. A–D. Results shown are from one representative experiment out of three experiments using IT#2 and IT#3 cells.
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Fig. 6. Internalization of hBD2 and/or hBD3 into infant tonsil cells inactivates intracellular HIV. (A) Polarized infant IT#2 tonsil epithelial cells were incubated with 40 ng/ml
of HIV-1SF33 virions for 1 h at 4 °C. Then, one set of cells was washed and trypsinized with 0.25% trypsin. Another set of cells was not treated with trypsin. Dissociated cells
were washed and lysed, and HIV p24 was examined by Western blot. (B) IT#2 cells were incubated with hBD2 and/or hBD3 (100 mg/ml of each in individual and 50 mg/ml of
each in combination) for 30 min at 4 °C. Cells were washed, and HIV-1SF33, HIV-1SF170 and HIV-192UG029 virions were added to the apical surfaces of polarized cells. Cells were
incubated for 2 h at 37 °C. Then, cells were trypsinized to remove uninternalized virions and equally divided into two tubes. Cells in one tube were lysed and used for
detection of intraepithelial HIV by using p24 ELISA (upper panel). Cells in the other tube were homogenized and used for infection of TZM-bl cells (lower panel). After 48 h,
HIV infection was measured by Bright-GloTM Luciferase Assay. (C) Polarized infant epithelial cells IT#3 were incubated with hBD2 and/or hBD3 (40 mg/ml of each in
individual and 20 mg/ml of each in combination) for 30 min at 4 °C. Cells were washed, and HIV-1SF33 virions were added to the apical surfaces of polarized cells for 2 h at
37 °C and viral infectivity was examined in TZM-bl cells. (D) hBD2 and/or hBD3 (100 mg/ml of each in individual and 50 mg/ml of each in combination) were resuspended in
pooled breast milk from 5 donors and added to the polarized infant IT#2 cells for 30 min at 4 °C. HIV-1SF33 was resuspended in breast milk and added to the cells for the next
2 h at 37 °C. Cells without breast milk served as a control. Cells were washed and trypsinized to remove uninternalized virions from the cell surface, homogenized, and used
to infect TZM-bl cells. B, C and D. Bars indicate standard errors of the means (n¼3). *Po0.01, **Po0.001, ***Po0.0001, compared with the HIV-uninfected control group.
Three independent experiments using IT#2 and IT#3 cells showed similar results, and representative data from one experiment are presented.
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polarized infant tonsil epithelial cells
To study internalization of hBDs into polarized tonsil epithelial
cells, we added recombinant hBD2 or hBD3 (100 mg/ml of each) to
the apical surfaces of hBD-negative polarized infant cells. Cells
without hBD treatment served as a control. After 30 min incuba-
tion at 37 °C, cells were ﬁxed, permeabilized and immunostained
for hBD2 or hBD3. Confocal immunoﬂuorescence analysis showed
that approximately 50% and 80% of cells became strongly positive
for hBD2 and hBD3, respectively (Fig. 5A, upper panels). The
vesicular pattern of the hBDs suggested their penetration into
endosomal compartments. Internalization of hBD2 and hBD3 was
also detected with lower concentration (40 mg/ml) of these pro-
teins (data not shown). HBD expression in untreated cells was
sparse; i.e., o1% of untreated (endogenous) cells were positive for
hBDs (Fig. 5A, lower panels). To study the internalization of hBDs
into polarized epithelial cells by Western blot assay, hBD2 or hBD3
was added to the apical surface as described above. After 30 min
incubation at 37 °C, the cells were washed, treated with hepar-
inase to remove uninternalized HSPG-bound hBDs and dissociated
with 0.25% trypsin. Intracellular hBD2 and hBD3 were detected by
Western blot, which showed that recombinant hBD2 and hBD3
rapidly penetrate into polarized infant tonsil epithelial cells
(Fig. 5B). Quantitative analysis of protein bands showed that
penetration of hBD3 was approximately 2 fold higher than pene-
tration of hBD2.In the next experiments we compared hBD internalization by
incubating hBD-exposed cells at 4 °C and 37 °C for 30 min. Cells
were then washed, treated with heparinase and dissociated with
0.25% trypsin. Quantitative analysis of Western blot data of inter-
nalized hBDs showed that incubation of cells at 4 °C substantially
(80–90%) inhibited the penetration of hBD2 and hBD3 into cells
(Fig. 5C). These ﬁndings suggest that hBD internalization occurred
by an endocytotic mechanism.
To study the role of HSPGs in cointernalization of hBD2 and
hBD3 with HIV, we incubated heparinase-treated and untreated
cells with hBDs at 4 °C for 30 min. As we showed above, incuba-
tion of hBDs at 4 °C should allow them to bind to the cell surface
but prevent their internalization into cells. Thus, this approach
was used to determine hBDs and HIV cointernalization. HBD-
bound cells at 4 °C were washed and incubated with HIV-1SF33 for
1 h at 37 °C. Detection of intracellular hBD2, hBD3 and HIV p24 by
Western blot showed that only trace amounts of internalized hBDs
were seen in heparinase-treated cells. In contrast, in untreated
cells approximately 7- and 5-fold more intracellular hBD2 and
hBD2, respectively, were detected than in heparinase-treated cells
(Fig. 5D). Detection of HIV p24 in heparinase-treated cells was also
substantially (4- to 7-fold) lower than that in untreated cells,
indicating that HSPGs play a role in cointernalization of hBDs and
HIV into oral epithelial cells.
To detect cointernalization of HBDs with HIV by confocal
microscopy, we ﬁrst incubated cells with hBD2 and hBD3 for
30 min at 4 °C. Cells were then washed and incubated with HIV-
1SF33 for 1 h at 37 °C. Confocal microscopy showed that both hBD2
Fig. 7. hBD2 and hBD3 inactivate HIV in early and late endosomal compartments of polarized infant tonsil epithelial cells. (A) hBD2 and hBD3 (50 mg/ml each) in combi-
nation were added to the apical surfaces of infant polarized epithelial cells IT#2 for 30 min at 4 °C. One set of cells was not treated with hBDs (left panel). Cells were washed
and incubated with HIV-1SF33 (200 ng/ml p24) for 2 h at 37 °C. Cells were dissociated with trypsin, and homogenized and vesicular fractions were separated in sucrose
gradients. Each fraction was examined for EEA-1, LAMP-1, hBD2, hBD3 and HIV p24 by Western blot. (B) Vesicular fractions 4, 5 and 6 (pool 1) and 7, 8, 9, and 10 (pool 2) were
combined and examined for HIV p24 by ELISA (upper panel). TZM-bl cells were infected with pool 1 and pool 2, and HIV infection was examined after 48 h (lower panel).
Bars indicate standard errors of the means. Results with similar trends were obtained in 2 independent experiments using IT#2 and IT#3 infant tonsil epithelial cells.
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thelial cells (Fig. 5E).
Internalized hBD2 and hBD3 reduce the infectious activity of intra-
cellular HIV
To determine if internalized hBDs inactivate intracellular virus,
hBD2 and/or hBD3 was added to the apical surfaces of polarized
infant tonsil epithelial cells for 30 min at 4 °C. Cells were then
washed, and HIV-1SF33, HIV-1SF170 or HIV-192UG029 was added to
the apical surfaces of polarized infant tonsil epithelial cells for 2 h
at 37 °C. Cells were trypsinized using 0.25% trypsin, which
removes attached virions from the cell surface. To conﬁrm this, we
examined trypsin-mediated removal of attached virions from the
cell surface. HIV-1SF33 was added to the apical surface of polarized
cells, which were incubated at 4 °C for 1 h. Cells were then washed
and either trypsinized or not. Next, cells were washed and lysed,
and HIV p24 Western blot assay was used to detect attached vir-
ions. No virions were detected after trypsin treatment (Fig. 6A),
indicating that our experimental conditions are optimized for
study of the infectious activity of only the internalized virions.
Following trypsin treatment, the hBDs- and HIV-incubated cells
were examined for viral entry and infectious activity of intracel-
lular virions. One set of epithelial cells was lysed and internalized
HIV was measured by ELISA. These data showed that hBD2 and
hBD3, individually or in combination, did not affect viral entry(Fig. 6B, upper panel). The other set of epithelial cells was dis-
rupted and used for infection of TZM-bl cells. Results showed that
the infectivity of intracellular virus was reduced by both hBD2 and
hBD3, alone and in combination (Fig. 6B, lower panel). Inactivation
of dual-tropic HIV-1SF33 virus by hBD2 and hBD3 was approxi-
mately 40% and 70%, respectively (Fig. 6B, lower panel). HBD2 and
hBD3 reduced infectivity of R5-tropic HIV-1SF170 by 20% and 40%,
respectively. Reduction of X4-tropic HIV-192UG029 virus infectivity
by both hBD2 and hBD3 was substantial, i.e. approximately 80%. In
general, hBD2- or hBD3-induced inactivation of R5-tropic virus
was lower than that of dual- and X4-tropic viruses. HIV inactiva-
tion by a combination of hBD2 and hBD3 led to a substantial
reduction (about 80–95%) in viral infectivity of all three viruses
(Fig. 6B, lower panel). These results indicate that cointernalization
of hBD2 and/or hBD3 with HIV in infant tonsillar epithelial cells
reduces considerably the infectivity of intracellular virions. Anti-
HIV effects were also detected in HIV-1SF33 virus at a lower con-
centration of hBD2 and/or hBD3 (40 ng/ml) (Fig. 6C). HIV infec-
tivity in the experiments above (Fig. 6B and C) was also tested in
PBMCs, and similar data were obtained (data not shown).
To determine whether hBD2 and/or hBD3 maintain anti-HIV
activity in the presence of human breast milk, we collected and
pooled breast milk from 5 donors. Polarized cells were pre-
incubated with hBDs and HIV-1SF33 in the presence or absence of
breast milk, and viral infectivity was examined in TZM-bl cells. The
data showed (i) that breast milk alone, in the absence of hBDs,
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hBDs, individually, retained their ability to inhibit HIV infectivity
in the presence of breast milk and (iii) that the combination of
hBD2 and -3, in the presence of breast milk, was best at inhibiting
HIV infectivity. A lower concentration of hBD2 and/or hBD3 (40 mg/
ml of each) in the presence of breast milk also showed an anti-HIV
effect in polarized infant tonsil cells (data not shown).
hBD2 and hBD3 reduce HIV infectivity in the vesicular/endosomal
compartments of polarized infant tonsil epithelial cells
To determine whether virus is inactivated within the vesicular/
endosomal compartments, we incubated polarized cells with
hBD2 and hBD3 in combination for 30 min at 4 °C. One set of cells
was not treated with hBDs. Cells were incubated with HIV-1SF33 for
2 h at 37 °C and vesicular/endosomal compartments were isolated
by cell fractionation. To identify the early and late endosomes in a
total of 13 fractions, each fraction was examined for EEA1 and
LAMP-1, respectively, by Western blot assay. Fractions 4, 5 and 6,
representing late endosomes, were positive for LAMP-1 (Fig. 7A).Fig. 8. hBD2 and hBD3 bind to intracellular HIV. (A) HIV-1SF33 at 200 ng/ml p24 was ad
cells, which were incubated for 2 h at 37 °C. Then, uninternalized HIV was removed wit
immunoprecipitated with anti-gp120 antibodies. hBD2 (left) and hBD3 (right) in gp12
polarized epithelial cells IT#1 were treated with heparinase or untreated. hBD2 or hBD
washed, and HIV-1SF33 (200 ng/ml) was added for 2 h at 37 °C. Extracellular HIV and hB
used for gp120 immunoprecipitation. (Upper panels) hBD2 and hBD3 were detected in gp
of the upper panels were blotted with anti-gp120 antibodies. (Lower panels) The gp120
and mean densities of pixels for each band are shown as a bar graph under each blot. (C)
panel B, and gp120 precipitates were separated under nonreducing conditions in 16% Tri
obtained from 2 independent experiments using infant IT#1 and IT#2 cells.EEA-1 was detected in fractions 7, 8, 9 and 10, which represent
early vesicles. In hBD-treated cells, both hBD2 and hBD3 were
detected in early and late endosomes. Endogenous hBDs were not
detected in cells not treated with hBD. HIV p24 Western blotting
also showed that HIV and both hBD2 and hBD3 were localized in
the early and late endosomal compartments (Fig. 7A).
To determine the role of hBDs in HIV infection, we combined
HIV containing late and early endosomal fractions from hBD-
treated and untreated cells into two independent pools. HIV p24
ELISA of these vesicular pools showed that approximately equal
numbers of virions were present in vesicular/endosomal com-
partments of hBD-treated and untreated polarized cells (Fig. 7B,
upper panel), indicating that hBD2 and hBD3 did not affect HIV
entry into vesicular/endosomal compartments. To determine the
infectivity of intravesicular HIV, TZM-bl cells were infected with
equal amounts of vesicular pool 1 and pool 2. Luciferase assay
showed that TZM-bl cells infected with vesicular fractions isolated
from hBD2- and hBD3-treated cells was reduced to 80–90% com-
pared to hBD-untreated cells (Fig. 7B, lower panel). These ﬁndingsded to the apical surfaces of polarized adult AT#1 and infant IT#1 tonsil epithelial
h trypsin, cells were homogenized, and the postnuclear supernatant was lysed and
0 precipitates were detected by Western blotting. (B) Apical membranes of infant
3 (100 mg/ml each) was added to the apical surfaces for 30 min at 4 °C. Cells were
Ds were removed with trypsin, cells were lysed, and postnuclear supernatant was
120 precipitates by Western blotting. (Middle panels) Immunoprecipitated samples
protein bands of immunoprecipitated samples were measured by ImageJ software
Polarized infant epithelial cells IT#1 were treated with hBDs and HIV as described in
s-glycine gel. hBD2 and hBD3 were detected by Western blotting. Similar data were
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within both the early and late vesicular/endosomal compartments.
hBD2–HIV and hBD3-HIV complexes internalized into vesicular/
endosomal compartments of infant oral epithelial cells, and hBD2 and
hBD3 form oligomers
To determine whether hBD2 and hBD3 bind to virions in the
vesicular compartments, we examined their binding to intracel-
lular HIV gp120 by immunoprecipitation and Western blot assays.
HIV-1SF33 at 200 ng/ml p24 was added to the apical surfaces of
polarized hBD-positive adult and hBD-negative infant tonsil epi-
thelial cells. Upon internalization of virions, hBD2 and hBD3 were
detected in gp120-immunoprecipitated samples from hBD-
positive adult tonsil cells but not from infant cells (Fig. 8A).
These results indicate that both hBDs bind to HIV in the vesicular
compartments of adult oral epithelial cells, which express high
levels of hBDs.
To determine if HSPG-facilitates hBD–HIV complex coin-
ternalization into endosomal compartments, we treated the apical
surfaces of polarized infant oral epithelial cells with or without
heparinase in prior hBD/HIV binding and entry procedures. Wes-
tern blotting of gp120 precipitates for hBD2 or hBD3 showed that
gp120-hBD binding was detected only in heparinase nontreated
cells (Fig. 8B, upper panels). The lack of gp120 binding to hBDs in
heparinase-treated cells indicates that the HSPG-mediated hBD–
HIV gp120 complex cointernalized into vesicular compartments.
Detection (Fig. 8B, middle panes) and measurement (lower panels)
of gp120 in the immunoprecipitated samples showed that intra-
cellular gp120 was lower in the heparinase treated cells than in
untreated cells due to reduction of HIV binding to the cell surface
(Fig. 4B). Nevertheless, these lower levels of intracellular gp120 in
heparinase treated cells did not coprecipitate with hBD2 and
hBD3, conﬁrming that HSPG play a role in cointernalization of the
hBD-HIV complex.
To determine if hBD2 and hBD3 form oligomers in the endo-
somal compartments, we examined these HIV-bound hBDs by
Western blot assay under nonreducing conditions. The results
showed that hBD2 and hBD3 were detected at 5 kDa, 10/
12 kDa and 15/17 kDa (Fig. 8C), indicating that these were
monomers, dimers and trimers, respectively; however, most of the
hBDs were detected as oligomers. These ﬁndings indicate that
HIV-bound hBD2 and hBD3 in the vesicular/endosomal compart-
ments were oligomerized.Discussion
To study the molecular mechanism of hBD-mediated HIV
inactivation in oral epithelial cells, we established polarized infant
tonsil keratinocytes, which do not express hBD2 and hBD3.
Application of recombinant hBD2 and hBD3 and HIV to the apical
(mucosal) surfaces of hBD-negative polarized infant cells showed
that both hBDs and HIV bound to the cell surface and were
internalized into vesicular/endosomal compartments. Although
hBD2 and hBD3 did not play a direct role in the infectivity of HIV
upon viral attachment to the cell surface, both defensins inde-
pendently and, in combination, reduced the infectious activity of
intracellular virus. These data are consistent with HIV inactivation
in adult oral epithelial cells expressing hBD2 and hBD3, and with
the preservation of viral infectivity by suppressing hBD2 and hBD3
expression using siRNA and intracellular neutralization of these
hBDs by speciﬁc antibodies (Tugizov et al., 2011).
Our results show that both hBD2 and hBD3 interact with HIV
envelope protein gp120 on the apical surface of polarized oral
epithelial cells. This interaction is facilitated by HSPG, which areexpressed on the apical surface of oral epithelial cells and simul-
taneously bind to hBD2, hBD3 and HIV gp120. The binding of hBD2
and hBD3 to HIV gp120 in the presence of HSPG and lack of hBD-
gp120 binding in the absence of HSPG in a cell-free system indi-
cate that HSPG is important for the interaction of hBDs with the
HIV viral envelope. Furthermore, lack of hBD binding to gp120 in
heparinase treated cells clearly indicates that these cell surface
proteoglycans play a critical role in the interaction of hBDs to
HIV gp120.
It is well documented that HIV gp120 binds to HSPG through
the V3 extracellular domain of gp120 (Batinic and Robey, 1992;
Harrop and Rider, 1998; Rider et al., 1994; Roderiquez et al., 1995;
Vives et al., 2005). hBD2 and hBD3's interaction with HSPG does
not compete with gp120 binding to HSPG. The heparan sulfate
chains express vast structural diversity on same cells, which may
facilitate their simultaneous binding to different proteins (Drey-
fuss et al., 2009; Sarrazin et al., 2011). Thus, it is possible that
chains of HSPG in the same oral epithelial cells may independently
bind to hBD2, hBD3, or HIV gp120, and that this may prevent
potential competition between hBD and HIV in binding to HSPG.
The interaction of hBD2 and hBD3 with HIV gp120 on the cell
surface and in the endosomal compartments indicates coin-
ternalization and cotrafﬁcking of hBDs and HIV into the same
endosomes. Defensins are internalized into cervical epithelial cells,
as shown by Hazrati et al. (Hazrati et al., 2006). Binding and
internalization of hBD3 was higher than that of hBD2, suggesting
that the binding afﬁnity of hBD3 to HSPG could be higher than the
binding afﬁnity of hBD2 to HSPG. Cointernalization of hBD2 and
hBD3 with HIV into oral epithelial cells was facilitated by HSPG,
which are a well-known receptors for the endocytosis of multiple
cellular and viral proteins and viruses, including HIV (Bobardt
et al., 2004b, 2007; Christianson and Belting, 2014; Connell and
Lortat-Jacob, 2013; Saidi et al., 2007).
The interaction of hBD2 and hBD3 with HIV gp120 on the cell
surface did not lead to viral inactivation, in contrast to coin-
ternalization of hBD2 and hBD3 with HIV into endosomal com-
partments. The intracellular antiviral function of hBD2 and hBD3
correlates with their oligomer formations. These ﬁndings suggest
that the internalization of hBDs and HIV into endosomal com-
partments creates a favorable environment for the oligomerization
of hBD2 and hBD3, thus increasing their antiviral function. It is
possible that molecular interactions between the hBDs and HIV, or
between hBDs and unidentiﬁed endosomal proteins in the vesi-
cular environment, may play a critical role in the induction of hBD
oligomerization. The molecular mechanisms of intravesicular
interactions between hBDs, HIV, and endosomal proteins in the
vesicular/endosomal compartments will require elucidation.
We have shown that hBD2 and hBD3 are colocalized with HIV
in the early endosomes of polarized oral epithelial cells (Tugizov
et al., 2011), which are sorting compartments with a nonacidic
environment (Jovic et al., 2010). Although HIV transcytosis through
these compartments should not be inactivated by neutral pH,
transcytosed virions were inactivated (Tugizov et al., 2011). Our
current data from puriﬁed endosomes show that hBD2 and hBD3
cointernalization with HIV into early endosomes causes inactiva-
tion of virus, indicating that viral inactivation during transcytosis
occurs in the early endosomes of polarized oral epithelial cells.
Notably, HIV isolated from the late endosomes in hBD-untreated
cells is infectious, suggesting entry of virus into the spherical,
nonacidic late endosomal compartment called a multivesicular
body (MVB) (Fader and Colombo, 2009; Piper and Katzmann,
2007). However, it is also possible that hBD-mediated HIV inacti-
vation occurs ﬁrst in the early endosomes, and that these inacti-
vated virions are later delivered into late endosomes, including
MVB. hBD penetration into both early and late MVBs is critical for
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intraepithelial clearance of the virus.
The molecular mechanisms of hBD2- and hBD3-mediated HIV
inactivation are not well understood. Defensins bind to biological
membranes and form multimeric pores, leading to the disruption
of membranes (Bonucci et al., 2013; Ganz et al., 1985; Hancock and
Lehrer, 1998; Lehrer and Ganz, 2002; Nizet et al., 2001; White
et al., 1995; Zasloff, 2002). It is possible that intravesicular HIV
inactivation in oral epithelial cells is due to hBD2- and hBD3-
mediated disruption of viral membranes, which could be sub-
stantially increased by cointernalization of the hBDs in the same
vesicular/endosomal compartments and by their oligomer forma-
tion. The role of oligomeric hBD2 and hBD3 in the disruption of
HIV membranes in the vesicles has yet to be demonstrated.
The binding of defensins to the viral surface may cause cross-
linking of viral glycoproteins, affecting their mobility (Leikina
et al., 2005). Immobile glycoproteins may not expose their fusion
domains and thus may not be able to induce the fusion of viral and
cellular membranes; i.e., become dysfunctional for viral entry. It is
possible that the interaction of hBD2 and/or hBD3 with intracel-
lular HIV gp120 in polarized oral epithelial cells may cross-link
viral envelope glycoproteins, leading to their immobilization. Oli-
gomerization of virion-bound hBDs in the vesicles may play a
critical role in the cross-linking and immobilization of HIV gp120.
Although transcytosis of HIV with immobile gp120 may still allow
the release of virus from epithelial cells, it may not be able to
infect CD4 T lymphocytes. Binding of immobile gp120 to CD4
cannot induce the conformational changes in gp120 that are cri-
tical for the exposure of fusion peptide of gp41 (Rizzuto et al.,
1998; Tamm and Han, 2000; Wilen et al., 2012).
We have shown that hBD2 and hBD3 are secreted from polar-
ized adult oral epithelial cells (Tugizov et al., 2011). HBD2 and
hBD3 were detected in saliva (Ghosh et al., 2007), suggesting that
they may be secreted from mucosal epithelium and/or salivary
glands into saliva. HBDs secreted into the mucosal environment
may bind to HSPG of the mucosal epithelium, which may facilitate
hBD binding to viral gp120 and internalization of hBD-bound HIV
into endosomal compartments of oral epithelial cells, where hBDs
are oligomerized and inactivate the intravesicular virions.
Functionally active oligomers of hBD2 and hBD3 in endosomal
compartments of polarized oral epithelial cells indicate that the
oligomers of hBDs rather than their monomers have a strong
antiviral effect in the inhibition of transcytotic transmission of HIV
through oral mucosal epithelium. HBDs may not be highly func-
tional in the inhibition of paracellular HIV transmission through
disrupted epithelium, because extracellular hBDs may not efﬁ-
ciently bind to viral envelope in the absence of HSPG and may not
form dimers/oligomers in the extracellular environment.
Human breast milk did not inhibit the anti-HIV activity of hBD2
and/or hBD3, suggesting that the presence of recombinant hBDs in
breast milk may reduce postnatal HIV MTCT. Breast milk without
hBDs reduced HIV infectivity by approximately 15%, which could
have been due to endogenous breast milk associated antiretroviral
proteins, including lactoferrin, mucin and tenescin-C (Fouda et al.,
2013; Habte et al., 2008; Moriuchi and Moriuchi, 2001; Newburg
and Walker, 2007). Breast milk contains hBD2, however, it was
detectable only in the colostrum (0.5 ng/ml), but not in the mature
breast milk (Savilahti et al., 2015).
In summary, our data show that recombinant hBD2 and hBD3
bind to and internalize into infant tonsil epithelial cells that
express very low levels of endogenous hBDs, which could be due
to developmental regulation of their expression (Meyerholz et al.,
2006; Patil et al., 2005; Starner et al., 2005). Cell surface HSPGs
play a critical role in simultaneous binding to hBD2 and hBD3
and to HIV gp120 upon viral attachment and in the subsequent
cointernalization of HIV and hBD into vesicular/endosomalcompartments of infant oral epithelial cells. hBD2- and/or hBD3-
mediated inactivation of HIV occurs in the vesicular/endosomal
compartments by formation of oligomer hBDs, which could be
critical for inhibiting the mother-to-child transmission of HIV. It
could also be a mechanism of the rare HIV oral transmission via
the adult oral epithelium, which expresses high levels of hBD2 and
hBD3 (Tugizov et al., 2011, 2012). The lack of hBD2 and hBD3
expression in fetal, neonatal, and infant oral epithelia could reduce
the innate protective function of oral epithelia and contribute to
the high rate of HIV MTCT. This idea is supported by the high level
of oral transmission of simian immunodeﬁciency virus in infant
macaques (Baba et al., 1996; Ruprecht et al., 1998). Our data sug-
gests that approaches designed to increase the levels of expression
of hBD2 and hBD3 in infant oral mucosal epithelium or the topical
application of recombinant hBD2 and hBD3 could prevent or
reduce postnatal HIV MTCT.Materials and methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and was approved by the Committee
on Human Research of the University of California, San Francisco
(IRB approval # H8597-30664-03). All subjects provided written
informed consent for the collection of tissue and breast milk
samples.
Viruses and cells
Laboratory-adapted dual (X4-R5)-tropic HIV-1SF33 and the pri-
mary isolates R5-tropic HIV-1SF170 and X4-tropic HIV-192UG029
were grown in peripheral blood mononuclear cell (PBMC), which
were obtained from HIV-negative donors. Before infection, PBMC
were activated with 2.5 mg/ml phytohemagglutinin (Sigma) and
1 mg/ml interleukin-2 (BD Biosciences) for 3 days.
TZM-bl cells, obtained from the NIH AIDS Research and Refer-
ence Reagent Program, were contributed by John Kappes and
Xiaoyun Wu. These cells are a genetically engineered HeLa cell
clone that expresses CD4, CXCR4, and CCR5 and contains Tat-
responsive reporter genes for ﬁreﬂy luciferase and Escherichia coli
β-galactosidase under regulatory control of an HIV-1 long terminal
repeat (Platt et al., 1998; Wei et al., 2002).
Primary oral epithelial keratinocytes were expanded from
tonsil tissue samples collected after routine tonsillectomies in
three adults 35, 41, and 44 years of age and referred to as AT#1,
AT#2 and AT#3, respectively. Furthermore, primary keratinocytes
were isolated from tonsils of three infants at 3 months and 2 and
3 years of age and referred to as IT#1, IT#2 and IT#3, respectively.
The keratinocytes were grown in KGM medium (Lonza), and the
purity of the epithelial cells was examined by detection of pan-
keratin using a cocktail of anti-keratin antibodies containing Ab-1
and Ab-2 (Thermo Fisher Scientiﬁc), and only those epithelial cell
populations that were 100% positive for keratin were used. Large
numbers of keratinocytes from each tissue were propagated at
early passages and frozen in liquid nitrogen.
Polarized cells were established in 0.45-mm Transwell two-
chamber ﬁlter inserts, as described in our previous work (Tugizov
et al., 2003, 2011, 2013a, 2013b). The polarity of epithelial cells was
veriﬁed by immunodetection of the tight junction protein ZO-1
and measurement of transepithelial resistance (TER) using a
Millicell-ERS voltohmmeter, as described in our previous work
(Tugizov et al., 2003, 2011, 2013a, 2013b).
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For immunoﬂuorescence assays, cells were ﬁxed with 4% par-
aformaldehyde and 2% sucrose in PBS for 5 min, and then per-
meabilized with 0.01% Triton X-100 in 4% paraformaldehyde for
5 min. For detection of hBD2 and hBD3, goat anti-hBD2 and goat
anti-hBD3 (R&D Systems) were used. HSPGs and GalCer were
detected with mouse monoclonal antibodies 10E4 (US Biological)
and MAB342 (Millipore), respectively. CCR5 and CXCR4 were
immunostained with mouse monoclonal antibodies (both from
R&D and provided by the NIH AIDS Reagent Program). For detec-
tion of HIV, mouse anti- p24 antibody was used (NIH AIDS Reagent
Program). Tight junction protein ZO-1 was detected using rabbit
antibody (Invitrogen). Secondary antibodies labeled with ﬂuor-
escein isothiocyanate or tetramethyl rhodamine isothiocyanate
were purchased from Jackson ImmunoResearch. The speciﬁcity of
each antibody was conﬁrmed by negative staining with the cor-
responding isotype control antibody. Cell nuclei were counter-
stained with TO-PRO-3 iodide (blue) or propidium iodide (red)
(Molecular Probes). Cells were analyzed by using a krypton-argon
laser coupled with a BioRad MRC2400 confocal head. The data
were analyzed by using BioRad LaserSharp software.
Western blot assay
Cells were extracted with 1.0% Triton X-100 buffer (150 mM
NaCl, 10 mM Tris/HCl, pH 8.0, and a cocktail of protease inhibitors).
Proteins were separated on a 4–20% gradient SDS-polyacrylamide
gel. hBD2 and hBD3 were detected by using mouse and goat
antibodies from Santa Cruz Biotechnology and R&D Systems.
Heparan sulfate proteoglycans (HSPG) were detected by using
mouse monoclonal antibody 7E12 (Millipore). Protein bands were
visualized by using ECL Western blotting detection reagents
(Amersham), and an equal protein load was conﬁrmed by detec-
tion of β-actin (Ambio). HIV gp120 and p24 were detected by using
mouse monoclonal antibodies ID6 and #24-2, respectively (both
from NIH AIDS Research and Reference Reagent Program).
Generation of recombinant hBD2 and hBD3
Recombinant hBD2 and hBD3 were generated as described
previously (Feng et al., 2005). Brieﬂy, hBD2 and hBD3 cDNA was
cloned into pET-30c (Novagen). IPTG was used to induce expres-
sion of the recombinant hBD2/3 His-tag fusion protein. Ni-NTA
afﬁnity chromatography was used to isolate hBD2/3 fusion protein.
Mature hBD2/3 was released by enterokinase (Novagen) digestion.
HBD2/3 was puriﬁed with RP-HPLC and identiﬁed by mass
spectroscopy.
hBD binding and penetration assays
The apical surfaces of polarized oral epithelial cells were pre-
treated with 10 U/ml heparinase (Sigma) for 30 min. For the hBD
binding assay, cells were washed with cold phosphate-buffered
saline (PBS, pH 7.2), and recombinant hBD2 or hBD3 was added to
the apical surfaces. Cells were incubated at 4 °C for 30 min and
washed 3 times with PBS; surface-bound hBDs were detected by
domain-speciﬁc labeling assay (see below). For hBD penetration,
hBD2 or hBD3 was added to the apical surfaces of polarized cells,
which were incubated for 30 min at 37 °C. Cells were washed and
trypsinized to remove uninternalized hBDs, and intracellular hBD2
and hBD3 were detected by Western blot. hBD2 and hBD3 binding
to the apical surfaces of infant oral epithelial cells in the presence
of anti- CXCR4, CCR5 and GalCer antibodies was examined by
using the following reagents: mouse monoclonal anti-CXCR4
(clone 12G5; 10 mg/ml), anti-CCR5 (pool of clone 2D7; 50 mg/ml),and mouse monoclonal anti-GalCer (25 mg/ml) (Millipore). Anti-
bodies were added to the apical membranes of polarized cells,
which were then incubated for 1 h at 4 °C before the addition of
hBDs. All antibodies to CXCR4 and CCR5 were provided by the NIH
AIDS Reagent Program. A parallel set of experiments was per-
formed in which cells were treated with a pool of appropriate
isotype controls for the anti-GalCer (IgG1a), CXCR4, and CCR5
(mouse IgG2a and IgG2b) antibodies. The concentrations of iso-
type antibodies were similar to the concentrations of speciﬁc
antibodies. Cells were washed, and hBD2 and hBD3 (100 mg/ml of
each) were added to cells, which were incubated at 4 °C for
30 min. Cells were washed, and hBD binding was examined by
domain-speciﬁc surface labeling assay.
Domain-selective surface labeling assay
Polarized cells were incubated with 200 mg/ml sulfo-NHS-LC-
biotin (Thermo Fisher Scientiﬁc Inc.) from apical or basolateral
membranes for 30 min as described in our previous work
(Suﬁawati and Tugizov, 2014; Tugizov et al., 2003; Xiao et al.,
2009). Cells were washed with Tris saline (10 mM Tris–HCl, pH 7.4,
120 mM NaCl), and extracted in 1% Triton X-100 lysis buffer con-
taining protease inhibitors. Biotinylated proteins were precipitated
with streptavidin–agarose beads in lysis buffer (Thermo Fisher
Scientiﬁc). Proteins were separated on a 4–20% Tris–glycine SDS-
polyacrylamide gel and transferred to nitrocellulose membranes
(GE Healthcare). HSPG were detected by using mouse monoclonal
antibody 7E12. Bands were visualized by using the ECL detection
system (GE Healthcare). To determine hBD2 and hBD3 binding to
HSPG on the apical surface, one set of cells was treated with
heparinase for 30 min, while a second set was not treated. Cells
were then washed, and recombinant hBD2 and hBD3 were added
for 1 h at 4 °C. Cells were biotinylated as described above and
lysed. hBD2 and hBD3 were detected by Western blot assay using
mouse monoclonal antibodies. To conﬁrm equal protein load, the
samples were examined for T-cell immunoglobulin and mucin
domain 1 (TIM-1) protein by Western blot using rabbit polyclonal
antibody (LSBio).
HIV attachment and entry assays in the presence or absence of hBD2
and hBD3
Recombinant hBD2 and hBD3 were obtained from Santa Cruz
Biotechnology, as well as from Dr. Aaron Weinberg's laboratory. All
experiments with hBD2 and hBD3 were performed in keratinocyte
growth medium (Lonza). The toxicity of hBDs on polarized cells
was examined by using an MTT Cell Viability Assay Kit (Biotium,
Inc.). One set of cells was pretreated with antibodies against HSPG
(25 mg/ml) or isotype control antibodies (25 mg/ml). Another set of
cells was pretreated with 10 U/ml heparinase (Sigma) for 30 min.
hBD2 and hBD3 were added to the apical surfaces of polarized
cells, and cells were incubated at 4 °C for 30 min. Cells were
washed 3 times with PBS, pH 7.0, and dual (X4-R5)-tropic HIV-
1SF33, and R5-tropic HIV-1SF170 or X4-tropic HIV-192UG029 virions
(40 ng/ml of each) were added to the apical surfaces of the cells.
For the HIV attachment assay, cells were incubated at 4 °C for 1 h
and then washed 3 times and lysed with Triton X-100 buffer.
Surface-bound HIV was measured by ELISA. For HIV entry, cells
were incubated with defensins at 4 °C for 30 min and then washed
and incubated with HIV at 37 °C for 2 h. Uninternalized virions
from the cell surface were removed with 0.25% trypsin as pre-
viously described (Tugizov et al., 2012). Cells were then lysed,
and internalized virus was examined by using p24 ELISA
(PerkinElmer).
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To determine the infectivity of HIV attached to the apical sur-
face of polarized cells, with or without hBD2 and hBD3, defensins
were added to polarized cells for 30 min at 4 °C, and then cells
were washed three times and incubated with virus for 1 h at 4 °C.
Cells were washed three times, dissociated from inserts by using
cell scrapers (CELLTREAT), and homogenized by using motor-
driven grinders connected with disposable pellet pestles, which
spin 2000–3000 round per minute (Pellet Pestle Cordless Motor,
Kimble Kontes). Pestle ends are specially designed to mate with
1.5 ml Eppendorf microtubes. Homogenization of cells using
spinning pellet pestles was performed for 1 min, leading to the
disruption of vesicles. Protein concentrations of homogenates
were measured by using the Bradford protein assay, and equal
amounts of homogenate were used to infect PBMC or TZM-bl cells.
PBMC infected with HIV were cultured for 1 or 2 weeks, and viral
infection was measured by ELISA detection of HIV p24. HIV-
infected TZM-bl cells were maintained for 2 days, and HIV infec-
tion was evaluated by detecting luciferase activity as described
previously (Sun et al., 2005). Luciferase expression was measured
using Bright-GloTM Luciferase Assay System (Promega) following
manufacturer’s instructions.
To determine the infectivity of HIV penetrating into polarized
epithelial cells, cells were incubated with defensins at 4 °C for
30 min and then washed and incubated with HIV for 2 h at 37 °C.
In some experiments, incubation of defensins and HIV was done in
the presence of breast milk from HIV-uninfected, healthy, breast-
feeding mothers. Breast milk was collected from healthy women
using breastpumps. All breast milk samples were mature, i.e., not
colostrum, and collected within 6 months of breast-feeding. A pool
of whole breast milk from 5 donors was used. Defensins were
resuspended in breast milk and added to the apical surfaces of
cells (0.3 ml per insert), which were incubated at 4 °C for 30 min.
Cells were then washed and incubated with HIV resuspended in
breast milk for 2 h at 37 °C. Cells were washed and trypsinized to
remove uninternalized virions from the cell surface, homogenized,
and used to infect PBMC or TZM-bl cells.
Isolation of vesicular/endosomal compartments containing HIV and
hBDs
Polarized cells were treated with or without hBD2 and hBD3
(50 mg/ml each) at 4 °C for 30 min and then washed. Cells were
exposed to HIV (200 ng/ml) at 37 °C for 2 h. Uninternalized virions
were removed with trypsin, and cells were homogenized in a
buffer containing 10 mM Tris (pH 7.5), 0.25 M sucrose, 1 mM EDTA,
and protease inhibitors as described (Grigorov et al., 2006). To
remove nuclei, homogenized cells were centrifuged at 1 000 rpm
for 10 min at 4 °C. The postnuclear supernatant was gently mixed
with sucrose to a ﬁnal concentration of 63%. Samples were placed
at the bottom of a centrifuge tube and overlaid with 45% sucrose
and then 10% sucrose. Samples were centrifuged at 35,000 rpm
for 16 h at 4 °C. Fractions were collected from the top, and each
fraction was analyzed by Western blotting using antibodies for
markers of early (early endosomal marker-1, EEA1) and late
(lysosome-associated membrane protein 1, LAMP-1) endosomes
(both from Abcam), HIV p24 (U.S. Biological), and hBD2 (Santa
Cruz Biotechnology) and hBD3 (RayBiotech).
HIV gp120 binding to hBD2 and hBD3
To detect HIV-1 gp120 binding to cell surface hBDs, recombi-
nant hBD2 and hBD3 (100 mg/ml each) were added to the apical
surfaces of polarized infant tonsil epithelial cells. Cells were
incubated at 4 °C for 30 min. Before incubation with hBD, one setof cells was treated with 10 U/ml heparinase (Sigma) for 30 min,
and cells were then washed and exposed to hBDs. Cells were
washed 3 times with cold PBS, pH 7.0, and HIV-1SF33 (200 ng/ml)
was added to the apical surfaces of polarized cells. Cells were
incubated at 4 °C for 1 h, washed and lysed, and HIV gp120 was
immunoprecipitated by using a mouse monoclonal antibody to
HIV-1 gp120 (ID6; NIH AIDS Research and Reference Reagent
Program). The hBD2 and hBD3 in the gp120 precipitates was
detected by Western blotting with mouse monoclonal antibodies.
To examine HIV gp120 binding to intracellular hBDs, we exposed
polarized adult and infant tonsil epithelial cells to HIV-1SF33 at
37 °C for 2 h. Uninternalized virions were then removed with
trypsin, cells were lysed, and HIV gp120 was immunoprecipitated
using mouse monoclonal antibodies ID6. hBD2 and hBD3 were
detected by Western blot using mouse monoclonal antibodies.
Detection of HIV gp120 protein in the gp120-immunoprecipitate
samples was performed by Western blot assay using the same ID6
antibodies that were used for the immunoprecipitation assays.
Proteins were separated by using Tris–glycine precast gels
(Invitrogen) under reducing and nonreducing conditions. For
reducing conditions, samples were denatured in Tris–glycine SDS
sample buffer containing 2.5% β-mercaptoethanol and run on the
gels by using Tris–glycine SDS running buffer (both from Invitro-
gen). For nonreducing conditions, samples were processed in Tris–
glycine native sample buffer without β-mercaptoethanol and run
on gels in Tris–glycine native running buffer, which does not
contain SDS (both from Invitrogen). Both denatured and native
samples were boiled at 80 °C for 5 min.
To examine hBD2 and hBD3 binding to HIV-1 gp120 in the
presence or absence of puriﬁed HSPG, HIV-1SF33 at 100 ng p24 /ml
was incubated with hBD2 or hBD3 (100 mg/ml of each) in the
presence or absence of puriﬁed HSPG (100 mg/ml) in cell culture
media for 1 h at 37 °C. Puriﬁed HSPGs and chondroitin sulfate
were purchased from Sigma-Aldrich. gp120 was then precipitated
and hBDs were detected by Western blot as described above.
Statistical analysis
Differences in p24 values of PBMC and TZM-bl cells infected
with HIV in the presence or absence of hBD2 or hBD3 were
compared by using Student's t-test; P values o0.05 were con-
sidered signiﬁcant.Acknowledgments
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